Effects of gastroesophageal reflux disease on sleep and outcomes.
Review article: Immediate-release proton-pump inhibitor therapy.
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Am J Manag Care.
Mody R, Bolge SC, Kannan H, Fass.J Manag Care Pharm.Yasuda S, Ohnishi A, Ogawa T,.Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.Ramser KL, Sprabery LR, Hamann GL,.Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia.
American College of Gastroenterology Annual Scientific Meeting; San Diego.
Delayed release dexlansoprazole amazing slow downer v1.6.1.apk in the treatment of gerd and erosive esophagitis.
Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting.
Nafcillin-induced platelet dysfunction and bleeding.
Moayyedi P, Armstrong D, Hunt RH,.Metz DC, Vakily M, Dixit T, Mulford.Abraham NS, Hlatky MA, Antman EM,.Serotonin syndrome and linezolid.Chey WD, Inadomi JM, Booher AM,.Sharma P, Shaheen NJ, Perez MC,.Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.Proton pump inhibitor attitudes and usage: A patient survey.